ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report

Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited effectiveness of existing treatment options. ALK rearrangement–positive is rare in pancreatic cancer, but may occur in those with KRAS-wild type. We present a 34-year-old young man with ALK rearrangement–posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Kai, Liu, Xiu, Li, Weihua, Yang, Yi, Ying, Jianming, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456297/
https://www.ncbi.nlm.nih.gov/pubmed/34568053
http://dx.doi.org/10.3389/fonc.2021.724815
_version_ 1784570846696701952
author Ou, Kai
Liu, Xiu
Li, Weihua
Yang, Yi
Ying, Jianming
Yang, Lin
author_facet Ou, Kai
Liu, Xiu
Li, Weihua
Yang, Yi
Ying, Jianming
Yang, Lin
author_sort Ou, Kai
collection PubMed
description Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited effectiveness of existing treatment options. ALK rearrangement–positive is rare in pancreatic cancer, but may occur in those with KRAS-wild type. We present a 34-year-old young man with ALK rearrangement–positive and KRAS-wild pancreatic cancer who had a remarkable response to crizotinib after resistance to prior chemotherapy and re-response to alectinib after brain metastases developed. This clinical observation suggests that comprehensive molecular profiling to guide targeted therapies is not only feasible, but also significantly improves survival outcomes for a subgroup of patients with pancreatic cancer.
format Online
Article
Text
id pubmed-8456297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84562972021-09-23 ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report Ou, Kai Liu, Xiu Li, Weihua Yang, Yi Ying, Jianming Yang, Lin Front Oncol Oncology Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited effectiveness of existing treatment options. ALK rearrangement–positive is rare in pancreatic cancer, but may occur in those with KRAS-wild type. We present a 34-year-old young man with ALK rearrangement–positive and KRAS-wild pancreatic cancer who had a remarkable response to crizotinib after resistance to prior chemotherapy and re-response to alectinib after brain metastases developed. This clinical observation suggests that comprehensive molecular profiling to guide targeted therapies is not only feasible, but also significantly improves survival outcomes for a subgroup of patients with pancreatic cancer. Frontiers Media S.A. 2021-09-06 /pmc/articles/PMC8456297/ /pubmed/34568053 http://dx.doi.org/10.3389/fonc.2021.724815 Text en Copyright © 2021 Ou, Liu, Li, Yang, Ying and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ou, Kai
Liu, Xiu
Li, Weihua
Yang, Yi
Ying, Jianming
Yang, Lin
ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title_full ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title_fullStr ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title_full_unstemmed ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title_short ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
title_sort alk rearrangement–positive pancreatic cancer with brain metastasis has remarkable response to alk inhibitors: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456297/
https://www.ncbi.nlm.nih.gov/pubmed/34568053
http://dx.doi.org/10.3389/fonc.2021.724815
work_keys_str_mv AT oukai alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport
AT liuxiu alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport
AT liweihua alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport
AT yangyi alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport
AT yingjianming alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport
AT yanglin alkrearrangementpositivepancreaticcancerwithbrainmetastasishasremarkableresponsetoalkinhibitorsacasereport

Ejemplares similares